Literature DB >> 9062353

Complex genetic contribution of the Apo AI-CIII-AIV gene cluster to familial combined hyperlipidemia. Identification of different susceptibility haplotypes.

G M Dallinga-Thie1, M van Linde-Sibenius Trip, J I Rotter, R M Cantor, X Bu, A J Lusis, T W de Bruin.   

Abstract

Familial combined hyperlipidemia (FCH) is a common genetic lipid disorder in Western societies. In a recent report (Dallinga-Thie, G.M., X.D. Bu, M. van Linde-Sibenius Trip, J.I. Rotter, A.J. Lusis, and T.W.A. de Bruin. J. Lipid Res., 1996, 36:136-147) we have studied three restriction enzyme polymorphisms: XmnI, and MspI sites 5' of the apo AI gene and SstI site in the 3' untranslated region of exon 4 of the apo CIII gene in 18 FCH pedigrees, including 18 probands, 178 hyperlipidemic relatives, 210 normolipidemic relatives, and 176 spouses. DNA variations in the apo AI-CIII-AIV gene cluster had a modifying effect on plasma triglycerides, LDL cholesterol, and apolipoprotein CIII levels. In this study, combinations of haplotypes were analyzed to further characterize their interactions and effect on the expression of severe hyperlipidemia in FCH subjects. A specific combination of haplotypes with one chromosome carrying the X1M1S2 (1-1-2) haplotype and the other the X2M2S1 haplotype (2-2-1) was significantly more frequent in hyperlipidemic relatives (6%) than in normolipidemic relatives (3%) and spouses (0.5%). Associated with this combination of haplotypes were significantly elevated plasma cholesterol (P < 0.0001), triglycerides (P < 0.0001), and apo CIII (P < 0.001) levels when compared to the wild type combination of haplotypes 1-1-1/1-1-1. The only spouse with this specific combination of haplotypes showed a severe hyperlipidemic phenotype, similar to FCH. Furthermore, nonparametric sibpair linkage analysis revealed significant linkage between these markers in the gene cluster and the FCH phenotype (MspI P = 0.0088, SstI P = 0.044, and XMS haplotype P = 0.037). The present findings confirm that the apo AI-CIII-IV gene cluster contributes to the FCH phenotype, but this contribution is genetically complex. An epistatic interaction between different haplotypes of the gene cluster was demonstrated. The S2 allele on one haplotype was synergistic to the X2M2 allele on the other haplotype in its hyperlipidemic effect. Therefore, two different susceptibility loci exist in the gene cluster, demonstrating the paradigm of complex genetic contribution to FCH.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9062353      PMCID: PMC507903          DOI: 10.1172/JCI119260

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  46 in total

1.  Pedigree and sib-pair linkage analysis suggest the apolipoprotein B gene is not the major gene influencing plasma apolipoprotein B levels.

Authors:  J Coresh; T H Beaty; P O Kwiterovich; S E Antonarakis
Journal:  Am J Hum Genet       Date:  1992-05       Impact factor: 11.025

2.  Multilocus genetic determinants of LDL particle size in coronary artery disease families.

Authors:  J I Rotter; X Bu; R M Cantor; C H Warden; J Brown; R J Gray; P J Blanche; R M Krauss; A J Lusis
Journal:  Am J Hum Genet       Date:  1996-03       Impact factor: 11.025

3.  Stable isotopes show a direct relation between VLDL apoB overproduction and serum triglyceride levels and indicate a metabolically and biochemically coherent basis for familial combined hyperlipidemia.

Authors:  S Venkatesan; P Cullen; P Pacy; D Halliday; J Scott
Journal:  Arterioscler Thromb       Date:  1993-07

4.  Genetic markers in the apo AI-CIII-AIV gene cluster for combined hyperlipidemia, hypertriglyceridemia, and predisposition to atherosclerosis.

Authors:  A Tybjaerg-Hansen; B G Nordestgaard; L U Gerdes; O Faergeman; S E Humphries
Journal:  Atherosclerosis       Date:  1993-05       Impact factor: 5.162

5.  An apolipoprotein CIII haplotype protective against hypertriglyceridemia is specified by promoter and 3' untranslated region polymorphisms.

Authors:  M Dammerman; L A Sandkuijl; J L Halaas; W Chung; J L Breslow
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-15       Impact factor: 11.205

6.  Impaired fatty acid metabolism in familial combined hyperlipidemia. A mechanism associating hepatic apolipoprotein B overproduction and insulin resistance.

Authors:  M Castro Cabezas; T W de Bruin; H W de Valk; C C Shoulders; H Jansen; D Willem Erkelens
Journal:  J Clin Invest       Date:  1993-07       Impact factor: 14.808

7.  The LPL gene in individuals with familial combined hyperlipidemia and decreased LPL activity.

Authors:  D N Nevin; J D Brunzell; S S Deeb
Journal:  Arterioscler Thromb       Date:  1994-06

8.  Analysis of DNA changes in the LPL gene in patients with familial combined hyperlipidemia.

Authors:  E Gagné; J Genest; H Zhang; L A Clarke; M R Hayden
Journal:  Arterioscler Thromb       Date:  1994-08

9.  Complex segregation analysis provides evidence for a major gene acting on serum triglyceride levels in 55 British families with familial combined hyperlipidemia.

Authors:  P Cullen; B Farren; J Scott; M Farrall
Journal:  Arterioscler Thromb       Date:  1994-08

10.  Familial combined hyperlipidemia and abnormal lipoprotein lipase.

Authors:  S P Babirak; B G Brown; J D Brunzell
Journal:  Arterioscler Thromb       Date:  1992-10
View more
  23 in total

Review 1.  Monogenic dyslipidemias: window on determinants of plasma lipoprotein metabolism.

Authors:  R A Hegele
Journal:  Am J Hum Genet       Date:  2001-10-26       Impact factor: 11.025

2.  Combined analysis of genome scans of dutch and finnish families reveals a susceptibility locus for high-density lipoprotein cholesterol on chromosome 16q.

Authors:  Päivi Pajukanta; Hooman Allayee; Kelly L Krass; Ali Kuraishy; Aino Soro; Heidi E Lilja; Rebecca Mar; Marja-Riitta Taskinen; Ilpo Nuotio; Markku Laakso; Jerome I Rotter; Tjerk W A de Bruin; Rita M Cantor; Aldons J Lusis; Leena Peltonen
Journal:  Am J Hum Genet       Date:  2003-03-12       Impact factor: 11.025

3.  The effects of scale: variation in the APOA1/C3/A4/A5 gene cluster.

Authors:  Stephanie M Fullerton; Anne V Buchanan; Vibhor A Sonpar; Scott L Taylor; Joshua D Smith; Christopher S Carlson; Veikko Salomaa; Jari H Stengård; Eric Boerwinkle; Andrew G Clark; Deborah A Nickerson; Kenneth M Weiss
Journal:  Hum Genet       Date:  2004-04-24       Impact factor: 4.132

Review 4.  The genetics of familial combined hyperlipidaemia.

Authors:  Martijn C G J Brouwers; Marleen M J van Greevenbroek; Coen D A Stehouwer; Jacqueline de Graaf; Anton F H Stalenhoef
Journal:  Nat Rev Endocrinol       Date:  2012-02-14       Impact factor: 43.330

5.  Genomewide scan for familial combined hyperlipidemia genes in finnish families, suggesting multiple susceptibility loci influencing triglyceride, cholesterol, and apolipoprotein B levels.

Authors:  P Pajukanta; J D Terwilliger; M Perola; T Hiekkalinna; I Nuotio; P Ellonen; M Parkkonen; J Hartiala; K Ylitalo; J Pihlajamäki; K Porkka; M Laakso; J Viikari; C Ehnholm; M R Taskinen; L Peltonen
Journal:  Am J Hum Genet       Date:  1999-05       Impact factor: 11.025

Review 6.  Next-generation gene discovery for variants of large impact on lipid traits.

Authors:  Elisabeth Rosenthal; Elizabeth Blue; Gail P Jarvik
Journal:  Curr Opin Lipidol       Date:  2015-04       Impact factor: 4.776

7.  Study of apolipoproteinc3 Sstl polymorphism in healthy volunteers from Northern India.

Authors:  S Chhabra; D P Agarwal; S Vasisht; K Luthra; R Narang; S C Manchanda; L M Srivastava; N Das
Journal:  Indian J Clin Biochem       Date:  2003-07

8.  Linkage and association between distinct variants of the APOA1/C3/A4/A5 gene cluster and familial combined hyperlipidemia.

Authors:  Sophie Eichenbaum-Voline; Michael Olivier; Emma L Jones; Rossitza P Naoumova; Bethan Jones; Brian Gau; Hetal N Patel; Mary Seed; D John Betteridge; David J Galton; Edward M Rubin; James Scott; Carol C Shoulders; Len A Pennacchio
Journal:  Arterioscler Thromb Vasc Biol       Date:  2003-10-09       Impact factor: 8.311

9.  Contribution of polymorphisms in the apolipoprotein AI-CIII-AIV cluster to hyperlipidaemia in patients with gout.

Authors:  F Cardona; F J Tinahones; E Collantes; A Escudero; E García-Fuentes; F J Soriguer
Journal:  Ann Rheum Dis       Date:  2004-04-28       Impact factor: 19.103

10.  Families with familial combined hyperlipidemia and families enriched for coronary artery disease share genetic determinants for the atherogenic lipoprotein phenotype.

Authors:  H Allayee; B E Aouizerat; R M Cantor; G M Dallinga-Thie; R M Krauss; C D Lanning; J I Rotter; A J Lusis; T W de Bruin
Journal:  Am J Hum Genet       Date:  1998-08       Impact factor: 11.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.